Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017)

BACKGROUND: As daily oral pre-exposure prophylaxis (PrEP) becomes standard for HIV prevention, routine use of PrEP is likely to increase within clinical trials of novel preventive agents. We describe the prevalence and characteristics of participants reporting non-study oral PrEP use within Microbic...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Acquir Immune Defic Syndr
मुख्य लेखकों: Liu, Albert Y., Norwood, Aliza, Gundacker, Holly, Carballo-Diéguez, Alex, Johnson, Sherri, Patterson, Karen, Bekker, Linda-Gail, Chariyalertsak, Suwat, Chitwarakorn, Anupong, Gonzales, Pedro, Holtz, Timothy H., Mayer, Kenneth H., Zorrilla, Carmen, Buchbinder, Susan, Piper, Jeanna M., Lama, Javier R., Cranston, Ross D.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2019
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6629432/
https://ncbi.nlm.nih.gov/pubmed/31299013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000002066
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन